Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Substitute for form 1449A/PTO Complete if Known Application Number 09/757,688 INFORMATION DISCLOSURE Filing Date January 11, 2001 STATEMENT BY APPLICANT First Named Inventor HEIL, Wolfgang Group Art Unit 1615 (use as many sheets as necessary) L.S. CHANNAVAJJALA **Examiner Name** of 3 Attorney Docket Number PLOVIN-0002-A Sheet 1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Decision in EP Opposition of EP Patent No. 1214076	
	2	Contraception, 43(1). 1991. 23-33., Melis G B et al., "A Comparative Study on the Effects of a monophasic Pill containing Desogestrel plus 20 Mug Ethynylestradiol a triphasic combination containing Gestodene on coagulatory factors." [c.f. MEDLINE an = 91168564]	
	3	Genazzani, A.R., F. Petraglia and A. Volpe (Ed.), Progress in Gynecology and Obstetrics; Second European Winter Conference in Gynecology and Obstetrics, Madonna Di Campliglio, Italy, March 1989. XXVI+944P. Parthenon Publishing Group Carnforth, England; Bilotta P et al., "Multicenter Clinical Trial on the new oral contraceptive containing 20 Mug Ethynylestradiol."	
	4	van Keep et al., 1981, The Workship moderators; reports presented at the 3rd International Congress on the menopause, held in Ostend, Belgium, in June 1981, under the auspices of the International Menopause Society, "The Controversial Climateric."	
	5	Deutsches Arzneibuch, 9. Ausgabe, Seite 105, 1986.	
	6	Guillebaud J., Br. J. Family Planning 12 (suppl), Seite 35-43, 1987, "The forgotten pill and the paramount importance of the pill free week."	
	7	Losert et al., Arzneimittelforschung 35(I), No. 2 (1985), "Progestogens with Antimineralocorticoid Activity."	
	8	Filshie at al., Contraception: Science and Practice, Butterworths, Seite 76-82, 1989, "Practical prescribing of the combined oral contraceptive pill."	
	9	Fioretti et al., Contraception, March 1987, Vol. 35, No. 3, "Clinical and metabolic study of a new pill containing 20 mcg Ethiny-estradiol plus 0.150 mg Desogestrel."	
	10	Peterson et al., American Journal of Obstetrics and Gynecology, Vol. 168, No. 1, Part 1, 1993, "Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women."	
	11	British Medical Journal, Vol. 290, Seite 1474-1475, 1985, "Missed pill – conception: fact or fiction?"	
	12	Spona et al., Contraception 54, 71-77, 1996, "Shorter pill-free interval in combined oral contraceptives decreases follicular development."	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.







Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute f	or form 1449A/PTC)		(Complete if Known
INICAL		DIC	OL OCUBE	Application Number	09/757,688
			CLOSURE	Filing Date	January 11, 2001
SIAI	EMENI B	Y AI	PPLICANT	First Named Inventor	HEIL, Wolfgang
				Group Art Unit	1615
(use as many she	ets as	necessary)	Examiner Name	L.S. CHANNAVAJJALA
Sheet	2	of	q	Attorney Docket Number	PLOVINLOOO2-A

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	13	Drife J.O., Annual Progress in Reproductive Medicine, 1993, "Oral contraception for the over-40s."	
	14	Kuhl et al., Das Klimakterium, 1987, s. 128-134, "Endokrine Veränderungen."	
	15	Fitgerald et al., Advances in Contraception 10, 5-18, 1994, "A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation."	
	16	Endrikat et al., Contraception 55, 131-137, 1997, "A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20µg gestodene and 30µg ethinylestradiol/75µg gestodene, with respect to efficacy, cycle control, and tolerance."	
	17	Sullivan et al., Fertility and Sterility 72, 1, 115-120, 1999, "Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60µg) and ethiny estradiol (15µg) on ovarian activity."	
	18	Endrikat et al., Contraception 64, 2, 99-105, 2001, "Double-blind, multicenter comparison of efficacy, cycle-control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 μg ethinyl estradiol and 75μg gestodene."	
	19	Elomaa et al., Contraception 60, 275-279, 1999, " Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment."	
	20	Krattenmacher et al., XVII Meeting I.S.G.S.H. 25-28/Nov/1995, page 55, "Effects of drospirenone on blood pressure and heart rate in rats measured by highly sensitive radiotelemetry."	
	21	European Journal of Contraception and Reproduction Health Care, 1999, 4 (Suppl. 2); 17-25, ycle control, safety and efficacy of a 24-day regimen of gestodene 60µg/ethinylestradiol 15µg and 21-day regimen of desogestrel 150µg/ethinyl-estradiol 20µg."	
	22	European Journal of Contraception and Reproduction Health Care, 1999, 4 (Suppl. 2); 9-15, "The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60µg and ethinylestradiol 15µg."	
	23	Pearlstein et al., submitted for publication, "Treatment of premenstrual dysphoric disorder with a new drospirenone – containing oral contraceptive formulation."	
	24	Leidenberger, Klinische Endokrinologie für Frauenärzte, Kapitel 8, pp. 123-140, 1998, "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen."	_
	25	Runnebaum et al., Gynecological Endocrinology and Reproductive Medicine, Vol. 1, Gynecological Endocrinology, pp. 455-468, 1997, "The Female Climacteric."	

Examiner	Date
Signature	Considered

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.







EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute f	or form 1449A/PTC)		(Complete if Known
INICAL		DIC	OL OCUBE	Application Number	09/757,688
			CLOSURE	Filing Date	January 11, 2001
SIAI	EMENI B	Y AI	PPLICANT	First Named Inventor	HEIL, Wolfgang
				Group Art Unit	1615
(use as many she	ets as	necessary)	Examiner Name	L.S. CHANNAVAJJALA
Sheet	2	of	q	Attorney Docket Number	PLOVINLOOO2-A

	I	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	26	Treloar, presented at the 3rd International Congress on the Menopause, Ostend, Belgium, pp. 249-269, 1981, "Menstrual Cyclicity and the PreMenopause."	
	27	Hargrove, J.T. et al., Am J. Obstet Gynecol., 1989 Oct; 161(4): 948-51 (Abstract); "Absorption of oral progesterone is influenced by vehicle and particle size.	
	28	McAuley, J.W. et al., Pharmacotherapy, 1996, May-June; 16(3): 453-57 (Abstract); "Oral administration of micronized progesterone: a review and more experience."	
	29	Bauer, et al., Vorwort 4. Auflage, 1993, 104-105 and 202-203	
	30	Voigt, Rudolf, Pharmazeutische Technologie for Studium and Beruf; 1993, pp 41, 42 and 194.	
	31	Müller, Bernd et al., Arzneiformenlehre Ein Lehrbuch für Pharmazeuten; 1980, page 24.	
	32	Opposers Grounds for Opposition against EP Patent No. 1257280-B1	
	33	Proprietor's Observations on Notice of Opposition in EP Patent No. 1257280-B1	

Examiner	Date	
Signature	Considered	

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.





EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.